GENE THERAPY, EARLY PROMISES, SUBSEQUENT PROBLEMS, AND RECENT BREAKTHROUGHS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

RAZI SOOFIYANI SAEIDEH; BARADARAN BEHZAD; LOTFIPOUR FARZANEH; KAZEMI TOHID; MOHAMMADNEJAD LEILA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Advanced Pharmaceutical Bulletin Year:2013 | Volume:3 | Issue:2 Page(s): 249-255

Download Full-Text

View:

319

Download:

148

Cites:

Information Journal Paper

Title

GENE THERAPY, EARLY PROMISES, SUBSEQUENT PROBLEMS, AND RECENT BREAKTHROUGHS

Author(s)

Keywords

GENE THERAPY

RECOMBINANT DNA TECHNOLOGY

VIRAL VECTORS

NON-VIRAL VECTORS

Abstract

GENE THERAPY is one of the most attractive fields in medicine. The concept of gene delivery to tissues for clinical applications has been discussed around half a century, but scientist’s ability to manipulate genetic material via RECOMBINANT DNA TECHNOLOGY made this purpose to reality. Various approaches, such as viral and NON-VIRAL VECTORS and physical methods, have been developed to make gene delivery safer and more efficient. While GENE THERAPY initially conceived as a way to treat life-threatening disorders (inborn errors, cancers) refractory to conventional treatment, to date GENE THERAPY is considered for many non–life-threatening conditions including those adversely influence on a patient’s quality of life. GENE THERAPY has made significant progress, including tangible success, although much slower than was initially predicted. Although, gene therapies still at a fairly primitive stage, it is firmly science based. There is justifiable hope that with enhanced pathobiological understanding and biotechnological improvements, GENE THERAPY will be a standard part of clinical practice within 20 years.

Cites

No record.

References

No record.

Cite

APA: Copy

RAZI SOOFIYANI, SAEIDEH, BARADARAN, BEHZAD, LOTFIPOUR, FARZANEH, KAZEMI, TOHID, & MOHAMMADNEJAD, LEILA. (2013). GENE THERAPY, EARLY PROMISES, SUBSEQUENT PROBLEMS, AND RECENT BREAKTHROUGHS. ADVANCED PHARMACEUTICAL BULLETIN, 3(2), 249-255. SID. https://sid.ir/paper/331811/en

Vancouver: Copy

RAZI SOOFIYANI SAEIDEH, BARADARAN BEHZAD, LOTFIPOUR FARZANEH, KAZEMI TOHID, MOHAMMADNEJAD LEILA. GENE THERAPY, EARLY PROMISES, SUBSEQUENT PROBLEMS, AND RECENT BREAKTHROUGHS. ADVANCED PHARMACEUTICAL BULLETIN[Internet]. 2013;3(2):249-255. Available from: https://sid.ir/paper/331811/en

IEEE: Copy

SAEIDEH RAZI SOOFIYANI, BEHZAD BARADARAN, FARZANEH LOTFIPOUR, TOHID KAZEMI, and LEILA MOHAMMADNEJAD, “GENE THERAPY, EARLY PROMISES, SUBSEQUENT PROBLEMS, AND RECENT BREAKTHROUGHS,” ADVANCED PHARMACEUTICAL BULLETIN, vol. 3, no. 2, pp. 249–255, 2013, [Online]. Available: https://sid.ir/paper/331811/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops